Ilyin et al. (Abstract)
Cellular Therapy and Transplantation (CTT), Vol. 3, No. 9
doi: 10.3205/ctt-2010-No9-abstract62
© The Authors. This abstract is provided under the following license: Creative Commons Attribution 3.0 Unported
Abstract accepted for "4th Raisa Gorbacheva Memorial Meeting on Hematopoietic Stem Cell Transplantation",
Saint Petersburg, Russia, September 18–20, 2010
The use of radiation therapy for patients with malignant lymphoma after high-dose chemotherapy and hematopoietic stem cell transplantation (HSCT)
Nikolay V. Ilyin1, Ekaterina N. Nikolaeva2, Julia N. Vinogradova1, Natalia B. Mikhailova3, Boris V. Afanasyev3, Anna V. Kritskaya3
1Federal State Institution “Russian Research Centre for Radiology and Surgical Technologies of the Federal Agency on High Technique Medical Care”; 2Saint-Petersburg Medical Academy of Postgraduate Education; 3Memorial R.M. Gorbacheva Institute of Children Hematology and Transplantation, Saint-Petersburg Pavlov State Medical University, Saint-Petersburg, Russia
Correspondence: Nikolay V. Ilyin, Federal State Institution “Russian Research Centre for Radiology and Surgical Technologies of the Federal Agency on High Technique Medical Care”, 70, Leningradskaya Street, Pesochny, St. Petersburg 197758, Russia, E-mail: crirr@peterlink.ru
Abstract
Aim: Relapse after high-dose chemotherapy and autologous hematopoietic stem cell transplantation (HSCT) is the main cause of mortality in lymphoma patients. The aim of our retrospective analysis is to demonstrate that local post-transplant radiation therapy improves the results of salvage therapy.
Methods: Between 2002- and 2010 radiation therapy was conducted in 8 patients after HSCT for non-Hodgkin’s (4 patients) and Hodgkin’s lymphoma (4 patients). The indications for HSCT were the following: consolidation of remission as the part of first line treatment –in 4 patients, relapse –in 1 patient, and primary resistance –in 3 patients. The reasons for radiation treatment were large residual masses after HSCT (5 patients), and progressive disease after HSCT (3 patients). Radiation therapy was conducted on the electron linear accelerator SL 75-5 (Philips). Mediastinal involvement (6 patients), peripheral lymph nodes (1 patient), and vertebrae (1 patient) were included in the field of radiation with a total dose of 34–38 Gy with different fractionation.
Results: There were no serious complications during radiotherapy. The following hematological toxicity was observed (scale RTOG): leucopenia grade 1 (n=1), grade 2 (n=6), grade 3 (n=1); thrombocytopenia grade 1 (n=6), and anemia grade 1 (n=2). Local control of disease was obtained in all patients. All patients are alive.
Conclusion: Radiation therapy is an important component in treatment of patients with malignant lymphoma, conducted as remission consolidation in patients after HSCT.
Keywords: lymphoma, radiation therapy, HSCT
